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Clinical Benefits of Remote Versus
Transtelephonic Monitoring of Implanted Pacemakers
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Objectives The purpose of this study was to evaluate remote pacemaker interrogation for the earlier diagnosis of clinically
actionable events compared with traditional transtelephonic monitoring and routine in-person evaluation.
Background Pacemaker patient follow-up procedures have evolved from evaluating devices with little programmability and
diagnostic information solely in person to transtelephonic rhythm strip recordings that allow monitoring of basic
device function. More recently developed remote monitoring technology leverages expanded device capabilities,
augmenting traditional transtelephonic monitoring to evaluate patients via full device interrogation.
Methods The time to first diagnosis of a clinically actionable event was compared in patients who were followed by re-
mote interrogation (Remote) and those who were followed per standard of care with office visits augmented by
transtelephonic monitoring (Control). Patients were randomized 2:1. Remote arm patients transmitted pace-
maker information at 3-month intervals. Control arm patients with a single-chamber pacemaker transmitted at
2-month intervals. Control arm patients with dual-chamber devices transmitted at 2-month intervals with an of-
fice visit at 6 months. All patients were seen in office at 12 months.
Results The mean time to first diagnosis of clinically actionable events was earlier in the Remote arm (5.7 months) than
in the Control arm (7.7 months). Three (2%) of the 190 events in the Control arm and 446 (66%) of 676 events
in the Remote arm were identified remotely.
Conclusions The strategic use of remote pacemaker interrogation follow-up detects actionable events that are potentially
important more quickly and more frequently than transtelephonic rhythm strip recordings. The use of transtele-
phonic rhythm strips for pacemaker follow-up is of little value except for battery status determinations. (PREFER
[Pacemaker Remote Follow-up Evaluation and Review]; NCT00294645) (J Am Coll Cardiol 2009;54:2012–9)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.001b
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Macemakers have been used for several decades to treat
atients with sinus node dysfunction and disorders of
he cardiac conduction system. The follow-up of pacemaker
atients has evolved over this period from in-person evalu-
tion of pulse generators with little or no programmability
o transtelephonic monitoring (TTM), which allows remote
ut limited assessment of device function.
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November 24, 2009:2012–9 Pacemaker Remote Managemento 2 months as the device battery nears the elective replace-
ent indicator voltage.
Early on, the longevity of the implantable pulse genera-
ors was very limited and the reliability was significantly less
han today, creating the need for increased surveillance.
here was little programmability or diagnostic information,
nd in-person evaluation was the only option for follow-up.
ver time, the device longevity increased, and TTM was
eveloped for the remote evaluation of the rudimentary
unctions of pacing systems.
The transtelephonic transmission of electrocardiographic
ata for the purpose of following pacemaker patients was
rst described by Furman et al. (1) in 1971 and has been
sed since that time for remote evaluations of patients with
acemakers (2). TTM allows the assessment of the battery
tatus and the analysis of sensing and stimulation function;
hat is, one is usually able to determine whether capture is
resent, intermittent, or absent and whether sensing is
resent, intermittent, or absent. TTM also provides a
imited electrocardiogram rhythm strip that does offer a
mall window of information about the patient’s rhythm at
he time of the transmission. It has been the standard of care
ince the 1970s (3).
Pacemakers have evolved so that current models not only
rovide heart rate support, but also continuously collect a
yriad of diagnostic information. The diagnostics provide
ngoing performance data about the pacing system such as
ensing and stimulation function, rate response history, lead
nd battery impedances, and battery capacity. Additionally,
here is the ability to report clinical information such as the
resence and nature of atrial arrhythmias, the percentage of
trial and ventricular pacing, and the presence of potentially
ethal ventricular arrhythmias. These data have the potential
o assist in clinical decision making for the management of
nderlying cardiac disease. For a decade or more, this
nformation was only available during an in-office evalua-
ion. Unfortunately, with the current standard of care (an
nnual visit plus TTM performed quarterly), these data are
ot seen in a timely fashion. Remote systems now allow the
cquisition of these data stored in the implanted device’s
emory from the convenience of the patient’s home. These
ata are transmitted to a central server that the patient’s
aregivers can access via a secure Internet-based interface.
imilar systems have been used for several years with
efibrillators (4–7). The drivers of this move to remote
ollow-up of defibrillator patients include the dramatic
xpansion of the defibrillator patient population, the devel-
pment of tools in the defibrillators that facilitate disease
anagement such as heart failure and arrhythmia diagnos-
ics, and the need for a more cost-effective follow-up
olution. In the future, there will likely be push technology
vailable in pacemakers as is currently available in wireless
mplantable cardioverter-defibrillators that will further re-
uce the data lag.
Previous studies have demonstrated that there is a significantate of clinical events, such as the presence of atrial tachycardia/
*trial fibrillation (AT/AF), in
acemaker patients (8,9). Before
he availability of remote interro-
ation, these events were typi-
ally discovered only at a stan-
ard device follow-up, which
ay not occur until 6 months
fter device implantation of a
ual-chamber pacemaker or af-
er 1 year for a single-chamber
acemaker. Infrequent access to these data has limited their
linical usefulness and the clinician’s ability for timely
ntervention.
To test the hypothesis that an Internet-based remote
acemaker interrogation system would be useful to identify
linically actionable information sooner than the current
tandard practice of TTM and in-office follow-up, a pro-
pective, randomized study was undertaken.
ethods
he PREFER (Pacemaker REmote Follow-up Evaluation
nd Review) study was a prospective, randomized, parallel,
nblinded, multicenter, open-label clinical trial to deter-
ine the utility of remote pacemaker interrogation for the
arlier diagnosis of clinically actionable events (CAEs)
ompared with the existing practice of TTM and routine
ffice visits. The study design was discussed previously in
etail (10). The study was conducted at 50 centers in the
.S. Institutional review board approval of the protocol was
btained from all centers, and all participants provided
ritten informed consent.
CAEs were defined as events that required a clinical
ecision to be made for potential alteration of the patient’s
edical management and/or required further medical as-
essment. These events, as defined in Chen et al. (10) and
isted in Table 1, collectively increase stroke risk, predispose
he patient to congestive heart failure, and may warrant
urther evaluation depending on clinical factors. Indicators
linically Actionable EventsTable 1 Clinically Actionable Events
AT/AF episodes 48 h (defined as 2 consecutive days in which the device
records at least 18 h of AT/AF per day)
New-onset AT/AF in patients with no history of AT/AF
Sensed ventricular rate of 100 beats/min during atrial arrhythmia for at least
20% of the time since previous device interrogation
Ventricular pacing that has increased by 30% since the last device interrogation
Nonsustained ventricular tachycardia 5 beats
Loss of capture*
Increase in pacing voltage threshold 1 V compared with the previous
interrogation*
Significant changes in atrial or ventricular lead impedance, defined as
impedance 200 or 2,000 , unstable lead impedance deemed to be
clinically actionable, 50% change in lead impedance since last
interrogation*
Elective replacement indicator or end of life present*
Abbreviations
and Acronyms
AT/AF  atrial tachycardia/
atrial fibrillation
CAE  clinically actionable
event
TTM  transtelephonic
monitoringNot used for analysis due to low numbers of events.
AT/AF  atrial tachycardia/atrial fibrillation.
o
i
c
t
a
s
d
a
P
t
p
m
p
(
w
a
P
(
M
a
s
d
d
p
c
S
t
b
g
w
e
d
v
d
i
m
t
d
t
T
s
t
f
s
i
a
C
o
p
a
b
w
l
S
T
l
e
t
T
s
a
T
f
i
r
P
b
h
K
f
s
v
t
t
a
C
A
n
p
d
a
p
O
p
f
2014 Crossley et al. JACC Vol. 54, No. 22, 2009
Pacemaker Remote Management November 24, 2009:2012–9f problems with the pacing system may also be noted,
ncluding a significant increase in stimulation threshold,
hanges in lead impedance, and indicator of battery deple-
ion. Each CAE requires, at minimum, physician diagnostic
ction and could require the addition of a medication or
urgical revision of the pacing system. Timeliness of this
iagnostic activity or lack of activity entirely could result in
diminished prognosis for the patient.
rimary objective. The primary objective of the study was
he incidence of first diagnosis of a CAE in patients whose
acemakers were followed by remote interrogation (Re-
ote) as opposed to those whose pacemakers were followed
er standard of care with office visits augmented by TTM
Control). The goal was earlier identification of events that
ere likely to require intervention and had the potential to
ffect the patient’s clinical course.
atient selection. Patients, as described in Chen et al.
10), were required to have a pacemaker compatible with the
edtronic CareLink Network remote monitoring system
nd were enrolled after the implantable pulse generator
ystem was deemed stable. Patients with both single- and
ual-chamber pacemakers were enrolled. All patients un-
erwent an in-office evaluation on study entry including
acing system evaluation, cardiovascular medical and surgi-
al history, and arrhythmia history.
tudy design. Patients were randomized in a 2:1 manner to
he Remote arm or the Control arm (Fig. 1). A permuted
lock randomization scheme was used. Pacemaker pro-
ramming was at the discretion of the responsible physician
ith the exception of 3 parameters. The atrial high rate
pisode value was set to “rolling,” so that the most recent
ata were always saved; the ventricular high rate episode
alue was set to “rolling,” and the ventricular minimum
Figure 1 Study Design
Depiction of required follow-up, remote and in-office, for patients
in the Remote and Control arms. TTM  transtelephonic monitoring.etection duration was set to 5 beats. Patient data for those dn the Remote arm were remotely transmitted at 3, 6, and 9
onths. The Control arm patients performed a TTM
ransmission at 2, 4, 8, and 10 months. At 6 months,
ual-chamber patients were seen in person, and a TTM
ransmission was performed in single-chamber patients.
he study concluded with an in-office visit at 12 months, as
hown in Figure 1. This TTM schedule was carried out at
he maximally permitted interval as described in the Centers
or Medicare & Medicaid Services guidelines (11). Un-
cheduled transmissions and in-person evaluations were
ncluded in the analysis. Data collected at all transmissions
nd in-person evaluations included medication changes,
AE collection, and clinician actions taken. Additionally,
n full pacemaker interrogation conducted remotely or in
erson, battery voltage, stimulation thresholds, impedances,
nd all stored data were collected. A parallel design was used
ecause it was anticipated that patients would prefer to stay
ith the more convenient remote telemetry arm than the
ess convenient TTM arm.
tatistical analysis. SAMPLE SIZE METHODS AND ASSUMP-
IONS. For the purposes of sample size calculation, simu-
ations were run to determine the sample size necessary to
valuate the primary objective while following patients
hrough quarterly CareLink transmissions compared with
TM transmissions and in-office visits per the Control arm
chedule. The sample size was chosen to achieve 80% power
nd   0.05. Only the first 5 actionable events listed in
able 1 were examined in estimating the time to first CAE
or the PREFER study.
Data from the A-HIRATE (Atrial High Rate Episodes
n Pacemaker Patients Trial) were used to estimate the event
ates for patients in the Remote and Control arms of the
REFER study (8,9). The A-HIRATE trial was chosen
ecause it was a study of pacemaker patients (many of whom
ad no history of documented AT/AF) with an implanted
appa 700 or 900 device. These patients had scheduled
ollow-up visits at 1, 6, and 12 months post-implantation.
For the purposes of event rate estimation, each patient’s
cheduled 6- and 12-month visits and any unscheduled
isits occurring during the period from their 1-month visit
o 13 months after the 1-month visit were used to determine
he event rate as if they were randomized to the Control
rm. In addition, for each patient, a 3- and 9-month
areLink transmission date was randomly generated.
NALYSIS OF PRIMARY OBJECTIVE. The time to first diag-
osis of a CAE was determined for each randomized
atient. Patients without a CAE were censored at the exit
ate (death, lost to follow-up, or study closure). The Peto
nd Peto modification of the Gehan-Wilcoxon test was
erformed (12). An intent-to-treat analysis was performed.
nly events diagnosed by the clinician counted toward the
rimary objective. A p value 0.05 indicated that the
reedom from first diagnosis of CAE was significantly
ifferent when patients were followed with remote interro-
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November 24, 2009:2012–9 Pacemaker Remote Managementation (Remote) compared with those being followed with
TM and having scheduled in-office visits (Control).
esults
articipant flow, recruitment, and demographics. Study
nrollment occurred from May 24, 2004, to March 30,
007. A total of 980 participants provided consent and were
creened. Of these, 83 were excluded from the cohort and
he remaining 897 were randomized in a 2:1 manner to
ither the Remote (n 602) or Control (n 295) arm (Fig.
). Summary statistics for the entire cohort are given in
able 2. There were no statistically significant differences in
aseline characteristics between the 2 arms.
rimary objective results. There were 382 patients with at
east 1 CAE, 111 patients in the Control arm and 271 in the
emote arm. Over an average follow-up of 375  140 days,
AEs were detected earlier in the Remote arm than in the
ontrol arm (p  0.0001). The mean and median times to
rst CAE in the Remote arm were 5.7 and 4.9 months,
espectively, whereas in the Control arm, the mean was 7.7
onths with a median of 6.3 months. The Kaplan-Meier
urvival curve in Figure 3 shows the survival analysis of time
o the first diagnosis of a CAE for both arms. This reflects
he data that were obtained for each patient, including data
btained both in-person and remotely. The stepwise ap-
earance of the event curves reflects the information ob-
ained during interrogations, which produces a sudden
ncrease in the event rate during each interrogation. Impor-
antly, only 3 (2%) of the 190 events in the TTM arm were
etected during a TTM transmission. All others were found
uring the in-office evaluations. In contrast, 446 (66%) of
76 total events were detected during remote interrogation
Figure 2 Patient Flowchart
The distribution, relative to inclusion in the analysis cohort and randomization
assignment, of all enrolled patients. Mean follow-up: 375  140 days.ollow-up in the Remote arm of the study. eAE summary. There were 866 CAEs reported in 382
atients in the study. A summary of the number of CAEs
xperienced per patient can be found in Table 3. The most
requent CAE reported was nonsustained ventricular tachy-
ardia, followed by AT/AF episodes lasting 48 h or longer.
igure 4 displays the number of CAEs per year by either
ome (Remote) or clinic for both arms. As can be seen, the
umber of CAEs discovered by TTM per year in the TTM
rm was very small (0.01). Most of the CAEs in this group
ere discovered at the time of the in-office evaluations.
iscussion
TM was introduced in the early days of cardiac pacing.
he primary functions of this monitoring technique were to
valuate the pacing system for sensing and to capture and to
valuate the status of the pacemaker battery. Although this
echnology has been the standard of care since the 1970s,
here have always been technical difficulties in the analysis of
he acquired data. It is often difficult to assess whether
apture and/or sensing are present (13). There are also other
ifficulties associated with TTM, including the logistics of
rranging phone calls, attachment of electrocardiography
quipment, and the need to follow phone instructions in a
atient population that is elderly and often hearing or
isually impaired.
The secondary function of TTM is evaluation of the
lectrocardiogram rhythm strip for the presence of arrhyth-
ias. This function is quite limited for paroxysmal arrhyth-
ias because the tracing is quite brief.
Beginning about the year 2000, pacemakers started re-
ording data that were useful in the clinical follow-up of the
atient. These data eventually included a full evaluation of
he device, information about lead function, and a detailed
rrhythmia log. These data are typically presented in a
rended fashion rather than a point in time. Unfortunately,
his information was only available to the physician when
he patient was seen in the office and a programmer was able
o extract the data. The utility was, therefore, somewhat
imited as there could have been 6 to 12 months between
vent occurrence and event discovery by the clinician.
Similarly, the critical analysis of a patient’s rhythm is
ften not possible given the resolution of TTM tracings.
he new Internet-based remote interrogation follow-up
ystem leverages all the power and memory of the new
acemaker devices by interrogating the pacemaker at home
nd then transmitting the data to a central computer. These
nternet-based systems reflect the natural progression of the
TM technology.
The results of the PREFER study demonstrate the
verwhelming superiority of the Internet-based full-
isclosure remote management approach over the tradi-
ional TTM approach for early identification of CAEs.
hese data are displayed in the survival curves of Figure 3.
he survival curves demonstrate a step function behavior atvery remote follow-up when full device data are available.
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Pacemaker Remote Management November 24, 2009:2012–9his is an artifact of the remote systems that requires
atients to initiate a device data transmission. There would
e an advantage to a pacemaker system that could alert a
linician via the remote interrogation system at the time of
n event occurrence, as is currently the case with defibrilla-
ors that use wireless telemetry to communicate with the
emote follow-up system. One would expect an enhanced
evel of care for these patients, with potential improved
utcomes. There is a potential for a reduction in overall
linic workload as the focus changes to exception-based
anagement and device checks, which only provide limited
nformation, decrease. This approach could, however, affect
he current workflow of a device clinic, thus needing further
onsideration if it is to be incorporated into practice.
The most significant result of the PREFER study is that
Patient DemographicsTable 2 Patient Demographics
Rem
(n  6
Sex, male 312 (
Age, yrs 68
Left ventricular ejection fraction, % 57
Cardiovascular history
Congestive heart failure 88 (
Coronary artery disease 195 (
Diabetes 130 (
Coronary artery disease 195 (
Diabetes 130 (
Hypertension 382 (
Myocardial infarction 82 (
Acute (6 months) 12 (
Chronic (6 months) 68 (
Syncope 204 (
Atrial arrhythmias
None 39 (
Atrial fibrillation 261 (
Paroxysmal 183 (
Persistent 53 (
Permanent 33 (
Atrial flutter 82 (
Atrial tachycardia 55 (
Sinus node dysfunction
Sinus bradycardia 18 (
Sick sinus syndrome 30 (
Brady-tachy syndrome 115 (
Chronotropic incompetence 30 (
Heart block
Mobitz I 26 (
Mobitz II 60 (
Third-degree block 180 (
Ventricular arrhythmias
None 222 (
Premature ventricular complexes 115 (
Nonsustained ventricular tachycardia 38 (
Sustained ventricular tachycardia 1 (
Values are presented as n (%) or mean  SD.nly 3 events were identified in the Control arm patients by eTM. The remaining 190 events identified in the Control
rm were identified by the scheduled in-office evaluations.
his verifies the long-held suspicion that TTM, although
seful for analysis of the pacemaker battery, may not be very
seful for the clinical follow-up of the patient. It is hoped
hat the early notification of events such as AT/AF and
ncreased ventricular pacing can aid in the detection or
revention of disease states such as stroke and progression to
ongestive heart failure. Remote pacemaker interrogation
ould potentially decrease the need for routine in-office
atient visits. This may potentially translate into positive
enefits for clinic efficiency and an increase in patient
onvenience.
This was the second study that provided clear evidence
hat pacemaker patients were not free of CAEs. Inter-
Control
(n  295)
p Value
(Remote vs. Control)
142 (48) 0.3
69 16.9 0.51
58 10.2 0.38
40 (14) 0.67
88 (30) 0.44
51 (17) 0.13
88 (30) 0.44
51 (17) 0.13
191 (65) 0.71
37 (13) 0.65
8 (3) 0.49
26 (9) 0.25
108 (37) 0.42
25 (8) 0.28
129 (44) 0.92
90 (31) 0.97
23 (8) 0.61
18 (6) 0.71
37 (13) 0.65
28 (9) 0.86
15 (5) 0.25
15 (2) 0.95
63 (21) 0.43
5 (2) 0.95
12 (4) 0.86
20 (7) 0.12
80 (27) 0.39
113 (38) 0.68
53 (18) 0.68
25 (8) 0.23
0 (0) 0.99ote
02)
52)
16.7
10.5
15)
32)
22)
32)
22)
63)
14)
2)
11)
34)
6)
43)
30)
9)
5)
14)
9)
3)
5)
19)
5)
4)
10)
30)
37)
19)
6)
0)stingly, the event rates in this study were lower than
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November 24, 2009:2012–9 Pacemaker Remote Managementhat was seen in the A-HIRATE trial. Lower event rates
ight have been due to different patient selection,
ifferent drug regimens, or the fact that end points for the
urrent study were only clinician-defined relevant events.
ome events in the A-HIRATE trial might not have met
he criteria for CAEs as used in this study. The
-HIRATE analysis used the device records to identify
ll events retrospectively.
At this time, there is still an important need for TTM.
here is still a significant number of patients who have
evices not supported by remote telemetry systems. TTM
echnology has evolved to be compatible with all devices,
hereas Internet-based systems are manufacturer spe-
Figure 3 Composite CAE
Survival curves represent the difference in probability of clinically actionable event
(CAE) identification between the Remote and Control arms. TTM  transtelephonic
CAE SummaryTable 3 CAE Summary
Event
Composite CAEs
NSVT
AT/AF 48 h
Sensed ventricular rate 100 beats/min during AT/AF
Ventricular pacing130%
New-onset AT/AF
Increase in ventricular pacing voltage threshold 1 V
Change in ventricular lead impedance
Loss of ventricular capture
Change in atrial lead impedance
Increase in atrial pacing voltage threshold 1 V
ERI/EOL
Loss of atrial captureAT/AF  atrial tachycardia/atrial fibrillation; CAE  clinically actionable ev
nonsustained ventricular tachycardia; TTM  transtelephonic monitoring.ific. TTM is not expected to be completely replaced in
he short term because many legacy devices are not
apable of remote transmission. Although TTM has
imited value in the evaluation of arrhythmias and device
unction, there is value in following the battery status of
lder pacemakers that are approaching battery depletion.
urther, we do not anticipate that remote interrogation
ill fully supplant in-office follow-up. Certain procedures
an only be done in person such as the examination of the
ound and reprogramming. In the future, if regulatory
urdles are overcome, we may even be able to further
nhance follow-up and achieve remote reprogramming of
acemakers for problem solving. Remote programming
toring.
No. of Events Reported per Patient
Remote Arm TTM Arm
1.123 0.644
0.517 0.308
0.198 0.105
0.188 0.098
0.101 0.064
0.061 0.037
0.018 0.017
0.012 0.003
0.010 0.000
0.010 0.003
0.005 0.003
0.003 0.000
0.000 0.003monient; ERI/EOL  elective replacement indicator/end of life; NSVT 
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Pacemaker Remote Management November 24, 2009:2012–9ill never replace the periodic direct evaluation of the
atient that is done now with both TTM and remote
valuation. It is important to realize that remote inter-
ogation does not prevent the acquisition of historical
nformation from the patient. It is standard practice in
ost centers for the arrhythmia nurse to call the patient,
lbeit after the remote transmission, take his or her
istory, and deliver the results of the remote evaluation.
What these data suggest is that the future of pacemaker
ollow-up is changing. Devices are becoming more sophis-
icated as they can now monitor their own operations and
etect clinical events. It is clear that the use of remote
ollow-up allows a more timely recognition of these events
ue to the ease with which a clinic can gain access to these
ata. This study supports the conclusions of the Heart
hythm Society/European Heart Rhythm Society expert
onsensus document that supports the use of remote
ollow-up to achieve the goals of pacemaker follow-up (14).
ew reimbursement codes (CPT) are now in use in the U.S.
hese codes allow reimbursement for remote interrogation
ollow-up procedures. With the clear improvement in data
nd the practicality of reimbursement, we certainly hope
hat there will be a rapid transition from the relatively
nefficacious TTM to the more efficacious remote interro-
ation follow-up.
tudy limitations. This study was not powered to detect a
ecrease in the clinical end points of stroke and congestive
eart failure. A larger study would be required to have the
ower to detect these benefits if they are present. This study
nvolved only the Medtronic CareLink system. Several
ther manufacturers have remote follow-up systems. The
pplicability of our findings to those systems is unknown.
hese findings are only applicable to devices for which
Figure 4 CAE Rate by Source
The number of clinically actionable events (CAEs) by their source. The number
of CAEs discovered by transtelephonic monitoring (TTM) per year in the TTM
arm was very small (0.01).emote follow-up is available. There remain many legacy
1evices implanted for which there is no remote follow-up
vailable.
onclusions
he strategic use of remote pacemaker interrogation
ollow-up detects clinically important and actionable events
ore quickly and frequently than transtelephonic rhythm
trip recordings. The value of TTM rhythm strips for
acemaker follow-up is limited to battery status determina-
ions. Remote device interrogation technology continues to
mprove patient care.
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